Hybridization of bioactive natural and non-natural compounds is one of the most promising and fundamentally novel approaches for the design of new lead structures and the discovery of novel and potent drugs in medicinal chemistry. A new treatment approach allows such drugs to be used in various related areas of neurology and psychiatry when it becomes necessary to alleviate emotional stress, induce sedation, stabilize or prevent mood swings in bipolar disorders of manic-depressive states. Hence, epileptic mood disorders, twilight clouding of consciousness, epileptic psychoses, epileptic personality changes, and emotional disturbances are known.

In recent years, with the use of antiepileptic drugs, mainly of the second generation, there has been a tendency to optimize results, aimed at the use of anticonvulsants with extended combined properties.

The primary tasks of the current stage of the treatment of epilepsy and epileptic syndromes are: the widespread introduction of new antiepileptic drugs with innovative mechanisms of action on the “target” of the pathological epileptic system the use of new drugs not only as an additional therapy for drug-resistant epilepsy, but, perhaps, a faster transition to new forms of drugs at the earliest stages of ineffective treatment with basic drugs. As a result, the treatment of epilepsy appears to be a very important social and socio-economic problem. Epilepsy is one of the most severe diseases of the nervous system, leading to serious complications and consequences in the form of reduced ability to work, social maladaptation, disability, and even premature death in patients. According to the WHO, more than 50 million people worldwide suffer from epilepsy.

System shock 2 hybrids